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Different etiologies such as drug toxicity, acute viral hepatitis B, or acetaminophen poison-
ing can cause acute liver injury or even acute liver failure (ALF). Excessive cell death of
hepatocytes in the liver is known to result in a strong hepatic inflammation. Experimental
murine models of liver injury highlighted the importance of hepatic macrophages, so-called
Kupffer cells, for initiating and driving this inflammatory response by releasing proinflam-
matory cytokines and chemokines including tumor necrosis factor (TNF), interleukin-6
(IL-6), IL-1beta, or monocyte-chemoattractant protein-1 (MCP-1, CCL2) as well as activating
other non-parenchymal liver cells, e.g., endothelial or hepatic stellate cells. Many of these
proinflammatory mediators can trigger hepatocytic cell death pathways, e.g., via caspase
activation, but also activate protective signaling pathways, e.g., via nuclear factor kappa
B (NF-κB). Recent studies in mice demonstrated that these macrophage actions largely
depend on the recruitment of monocytes into the liver, namely of the inflammatory Ly6c+
(Gr1+) monocyte subset as precursors of tissue macrophages. The chemokine receptor
CCR2 and its ligand MCP-1/CCL2 promote monocyte subset infiltration upon liver injury. In
contrast, the chemokine receptor CX3CR1 and its ligand fractalkine (CX3CL1) are important
negative regulators of monocyte infiltration by controlling their survival and differentiation
into functionally diverse macrophage subsets upon injury. The recently identified cellular
and molecular pathways for monocyte subset recruitment, macrophage differentiation,
and interactions with other hepatic cell types in the injured liver may therefore represent
interesting novel targets for future therapeutic approaches in ALF.
Keywords: liver injury, acute liver failure, macrophages, monocytes,TNF-alpha, chemokines, CCR2, review
INTRODUCTION
Acute liver injury (ALI) and acute liver failure (ALF) represent
different severity stages of a sudden deterioration of liver function
without evidence for prior chronic liver disease. It is a dreaded
disease condition due to its tremendous morbidity and mortal-
ity without adequate treatment. Clinical hallmarks of ALF are
coagulopathy (defined as an INR> 1.5) and mental alterations
(i.e., hepatic encephalopathy of any degree) within a 26-weeks
time-frame after the initial symptoms (Bernal et al., 2010). The
latter clinical condition is absent in ALI in which coagulation
abnormalities are predominant. The annual incidence of ALF is
estimated at one to six cases per million in the developed world
but may be higher in endemic regions of viral hepatitis (Bernal
et al., 2010). Due to insufficient surveillance and reporting systems
and lack of consistent diagnostic criteria accurate data concerning
Abbreviations: ALF,acute liver failure;ALI,acute liver injury;APAP,acetaminophen;
CCl4, carbon tetrachloride; CCL, C-C motif chemokine ligand; CCR, C-C motif
chemokine receptor; ConA, Concanavalin A; CXC, C-X-C motif chemokine; DC,
dendritic cell(s); GalN, d-galactosamine; HSC, hepatic stellate cell(s); IFN, inter-
feron; IL, interleukin; iNOs, induced nitric oxide synthetase; INR, international nor-
malized ratio; I/R, ischemia/reperfusion; KC, Kupffer cell(s); LSEC, liver sinusoidal
endothelial cell(s); LPS, lipopolysaccharide; MCP-1, monocyte-chemoattractant
protein-1; NF-κB, nuclear factor kappa B; NK-cell, natural killer cell; TNF, tumor
necrosis factor.
the global epidemiology of ALI are scarce. Drug-induced liver
injury as a common underlying cause is estimated to affect 44,000
individuals in the US per year (Bell and Chalasani, 2009). Mis-
cellaneous causes of acute liver deterioration exist, and etiology is
the best predictor of clinical outcome (Ostapowicz et al., 2002).
In major parts of the western hemisphere acute dose-dependent
acetaminophen (paracetamol) toxicity is the most prevalent cause
of ALF, whereas viral agents (mainly hepatitis A, B, or E virus)
predominate in developing countries. In recent years, idiosyn-
cratic, non-acetaminophen, drug-induced hepatotoxicity became
a major etiology of ALF in Europe (Canbay et al., 2011). ALF is a
systemic disease. Owing to its devastating nature implications of
liver failure rapidly affect virtually all vital organs eventually lead-
ing to multi-organ failure. Despite remarkable progress in disease
management and understanding of basic molecular mechanisms
involved, disease-specific, targeted therapies cannot be provided
in a considerable proportion of cases where liver transplantation
constitutes the sole medical mean to prevent death.
Local and circulatory components of the innate immune system
fundamentally shape the outcome of the immunological response
to an acute hepatic insult. There is a robust body of evidence that
hepatic macrophages (traditionally called “Kupffer cells,” KCs) are
essential players in the propagation of acute liver damage. These
cells attracted much attention lately in the context of chronic
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liver inflammation due to their dual pro- and antifibrotic quali-
ties (Zimmermann and Tacke, 2011) but evidence for their critical
involvement in fulminant hepatitis even date back several decades.
Ever since, the evolvement of intriguing techniques to impact
KC function has paved the way for a deepened knowledge and
enabled us to decipher detrimental as well as beneficial aspects
of KC activity. The present review intends to focus on hepatic
macrophages in ALI as well as on monocytes, the bone-marrow-
derived macrophage precursors that are vigorously recruited upon
liver damage. Chemokine pathways governing this process will be
a main focus in the subsequent sections, because interference with
these pathways might perspectively allow developing novel and
effective therapeutic approaches for ALF in the near future.
RESIDENT AND INFILTRATING HEPATIC MACROPHAGES
DURING HOMEOSTASIS AND INJURY
GENERAL ASPECTS OF LIVER ANATOMY AND MICROVASCULATURE
The liver is not only the largest solid organ of the human body
but also possesses the most extensive reticuloendothelial system
(RES), thus playing a central role in the immune response against
invading pathogens. It is unique in its property as an organ that
encounters all the foreign material adsorbed from the intestine
after digestion including food-derived antigens and environmen-
tal toxins (Gao et al., 2008). In addition, blood floating into
the liver via the portal vein (accounting for ∼80% of total liver
blood supply) contains microbial components even under steady
state conditions with lipopolysaccharide (LPS) from gut-derived
Gram-negative germs representing some of the most prominent
bacterial constituents. Moreover, due to an arterial blood sup-
ply the liver also samples antigens from systemic circulation. The
hepatic microvasculature is composed of liver sinusoids that are
lined by highly specialized liver sinusoidal endothelial cells (LSEC)
that tremendously differ from generic vascular endothelium in
terms of phenotype, surface markers, and function (Lalor et al.,
2006). Portal venous and arterial vessel branches supply the sinu-
soids with blood. Sinusoidal fenestrations and the lack of a basal
membrane facilitate the delivery of solutes across the subendothe-
lial space of Dissé to the hepatocytes which constitute the hepatic
parenchyma. Signals evoked by invading macro-material and cel-
lular effectors rely on active recruitment via sinusoidal cells or
endocytosis/phagocytosis and cytokine-release of resident phago-
cytic cells. Following drainage into the central vein the “liver-
modified” blood reaches systemic circulation through the vena
cava inferior.
KUPFFER CELLS ARE RESIDENT MACROPHAGES AND FULFILL
ESSENTIAL TASKS DURING STEADY STATE
Owing to the direct vascular connection to the splanchnic organs
as a source of potential environmental and inherent threats, inte-
gral parts of the innate immune system are highly enriched in the
liver. This renders the liver as an immunological organ with pre-
dominant innate immune functions (Racanelli and Rehermann,
2006; Gao et al., 2008). Apart from resident immune cells that
respond to exterior and interior damaging influences, the liver
is also source of a host of soluble factors encompassing acute-
phase-proteins, complement factors, cytokines, and chemokines,
which all contribute to the meticulous orchestration of immune
response to various stimuli (Ishibashi et al., 2009). However, the
liver is perpetually confronted with harmless nutrient-borne anti-
gens and low levels of LPS and other microbial products. Those
do not represent an inflammatory stimulus in steady state condi-
tions but elicit immunosuppressive responses in order to prevent
constant detrimental immune activation (Tacke et al., 2009). Intra-
hepatic macrophages accommodate for both opposing scenarios:
promoting immune tolerance during homeostasis as well as imple-
menting proinflammatory mechanisms in acute and chronic liver
injury. KCs traditionally denote hepatic (resident) macrophages
and represent up to 80–90% of the total body macrophage pool
(Ishibashi et al., 2009). Together with LSEC, hepatic stellate cells
(HSC), and local immune cells [in particular atypical T-cells, NK-
cells (pit cells), and hepatic dendritic cells (DCs)] KCs constitute
the non-parenchymal liver cells. They dwell in the lumen of liver
sinusoids in close contact to the sinusoidal endothelial cells and
sense the circulating blood for food-borne antigens and micro-
bial constituents stemming from the splanchnic circulation. The
sinusoidal site also guarantees intimate contact and communica-
tion with immune cells that enter the liver via the portal vein.
In the non-inflamed liver one of the key functions of KCs is the
removal of insoluble macromolecules through phagocytosis medi-
ated by a wide repertoire of pattern-recognition receptors (PRRs)
on their surface including scavenger receptors SR-AI and SR-AII,
mannose receptor, and Fc-γ receptors (Gao et al., 2008; Figure 1).
Thereby, hepatic macrophages eliminate potential harmful threats
elicited by degenerated cells, microbes, immune complexes, and
toxins (Kolios et al., 2006). KC show functional disparities related
to their localization within the liver lobule (Bilzer et al., 2006).
Periportal KCs, which are the first macrophages to encounter
inflowing portal blood, are more abundant, bigger in size, and
exhibit greater phagocytic and lysosomal capacities in addition
to an increased production of inflammatory mediators [such as
interleukin-1 (IL-1) and tumor necrosis factor (TNF) alpha (TNF-
alpha)], in comparison to those hepatic macrophages located in
the midzonal area and around the central vein (Sleyster and Knook,
1982; Hoedemakers et al., 1995). Moreover, KCs are not entirely
static in the sinusoidal lumen but migrate across the sinusoidal
walls and are capable of reducing the sinusoidal blood velocity
hence supporting the contact of circulating immune cells with
sinusoidal endothelial cells (MacPhee et al., 1992, 1995).
ORIGIN AND PHENOTYPE OF KCs DURING ABSENCE OR PRESENCE OF
HEPATIC INJURY
In absence of liver inflammation, the number of intrahep-
atic macrophages is maintained at constant numbers. Vari-
ous cytokines comprising IL-1, IL-4, interferon-gamma (IFN-
gamma), granulocyte–macrophage colony-stimulating factor
(GM-CSF), and other hematopoietic factors promote macrophage
apoptosis and survival in vitro (Naito et al., 2004). Results of
studies covering the life span of KCs are inconsistent and range
between 14 days and several months (Naito et al., 2004). Inter-
estingly, even in monocytopenic species KC persistence in situ
may exceed 6 weeks, suggesting that KCs constitute long-lived
resident macrophages (Naito et al., 2004). Nevertheless, con-
stant turnover is present and hepatic macrophages are inces-
santly repopulated. Previous concepts of resident macrophages
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FIGURE 1 | Kupffer cell (KC)/Macrophage (MΦ) function during liver
homeostasis. Phagocytosis and induction of immune tolerance as the two
main functions of KCs/hepatic MΦ in the steady state are depicted here.
KCs reside in the liver sinusoids in close proximity to sinusoidal endothelial
cells (LSEC) and immune cells entering the liver microvasculature mainly
through the portal vein. KCs express a broad range of surface receptors
mediating phagocytosis, which renders these cells as highly effective filters
of endogenous and exogenous antigens. Complement receptors mediate
removal of complement-opsonized material. Circulating non-opsonized
immune globulin complexes are cleared through Fc-γ Receptors. Insoluble
macromolecules from multiple sources are effectively cleared after binding
to Scavenger Receptors including CD163 for senescent erythrocytes.
Molecules with a mannosyl motif are phagocytized following engagement
of mannose receptors. Engulfment of apoptotic cell constituents can
induce secretion of immunosuppressive IL-10 which likely contributes to the
immune modulatory function of quiescent KCs. Constant exposure to
gut-derived LPS via TLR4 also results in expression of IL-10 and PGE2 that
can directly inhibit T-cell and NK-cell function and mediate down-regulation
of co-stimulatory proteins including CD80, CD86, and MHC class II on
endothelial cells, dendritic cells, and KCs constituting liver APCs, which
further attenuates T-cell activation. KC-secreted PD-L1 and release of
apoptosis-inducing mediators (TRAIL, FasL) contribute to suppression of
adaptive and innate immune response through inactivation/elimination of
T-cells and NK-cells. IL-10, PGE2, and TNF-alpha lead to reduced expression
of adhesion molecules (VCAM-1; ICAM-1) on LSEC, thereby limiting
leukocyte influx. Abbreviations: APC, antigen presenting cell; CR,
complement receptor; FasL, Fas ligand; ICAM-1, intercellular adhesion
molecule 1; PD-L, programmed cell death 1 ligand 1; PGE2, prostaglandin
E2; SR-AI/II, scavenger receptor AI/AII; TLR4, toll-like receptor 4; TRAIL,
tumor necrosis factor related apoptosis-inducing ligand; VCAM-1, vascular
adhesion molecular 1.
deriving from precursor cells (Yamamoto et al., 1996; Naito
et al., 1997; Duffield et al., 2005) have been refuted by more
recent studies that indicate that a significant extent of repopu-
lation of these cells is from bone-marrow-derived myeloid pre-
cursors (Klein et al., 2007). In line, in one study only 1.5% of
hepatic macrophages incorporated 3H-thymidine during steady
state, indicative of a low proliferation index (Crofton et al., 1978).
In acute and chronic liver injury the intrahepatic macrophage
count is massively expanded following the influx of peripheral
monocytes (Figure 2) rather than augmentation of tissue-resident
macrophages (Duffield et al., 2005; Imamura et al., 2005; Holt et al.,
2008; Karlmark et al., 2009; Zimmermann et al., 2010). However, a
FIGURE 2 | Kupffer cell (KC)/Macrophage (MΦ) contribution to acute
liver injury. Acute hepatocyte damage in response to multitude events
leads to release of various DAMPs including HSPs and HMGB-1, which bind
to TLR4 on KCs, and other cell contents (RNA, DNA) binding to various
TLRs. TLR4 engagement activates NF-κB pathways in KC resulting in the
synthesis of a myriad of proinflammatory cytokines, chemokines, reactive
oxygen, and nitrogen species. KC-secreted TNF-alpha is central in the
augmentation of liver injury mainly by inducing hepatocyte apoptosis, but
also by deterioration of hepatic microcirculation through swelling and
activation of endothelial cells with subsequent sinusoidal platelet
aggregation and facilitation of peripheral immune cells entry. Activated KCs
secrete IL-1beta and CXC chemokines such as CXCL2 and CXCL8 (IL-8),
whereby neutrophils are massively attracted and start releasing ROS and
proteases evoking hepatocyte necrosis. In addition, KCs, injured
hepatocytes and activated hepatic stellate cells secrete CCL2 and other CC
chemokines mediating liver influx of bone-marrow-derived monocytes that
expand the local macrophage pool. Hepatic macrophages are also
stimulated by IFN-gamma from resident and recruited T-cells and NK-cells
and by C5a. KCs actively govern NK cell activation and recruitment by the
production of IL-12/IL-18 which in turn induces hepatocyte death via
membrane-bound FasL. High levels of LPS arising from Gram-negative
bacteria in the context of increased bacterial translocation during acute liver
injury magnify the activation the liver macrophages. As a counter-regulatory
effect, hepatic macrophages also secrete IL-4, IL-6, and IL-10 amongst
others that may dampen hepatic injury by either direct or indirect
mechanisms. Engulfment of cell debris may either contain or amplify tissue
injury (not depicted here). The blue box in the right lower corner illustrates
important proapoptotic and prosurvival pathways in hepatocytes after
binding of KC-related effector molecules during acute liver injury. TNF-alpha
elicits both apoptosis (mainly via TNF-R1 and subsequent downstream
signaling involving TRADD, FADD, and effector caspases) and cell survival
through activation of NF-κB downstream cascade. Soluble and
membrane-bound FasL derived from activated KCs and NK-cells also leads
to caspase-dependent cell death after direct engagement of FADD. IL-6
complexes with gp80 and gp130 resulting in STAT3 activation via Janus
kinases (JAKs) that can promote cell protection. Abbreviations: C5a,
complement factor 5a; FADD, Fas-associated death domain; HMGB-1, high
mobility group box-1; HSP, heat-shock protein; IL, interleukin; NF-κB,
nuclear-factor-kappaB; ROS, reactive oxygen species; STAT3, signal
transducer and activator of transcription 3; TNFa, tumor necrosis factor
alpha; TRADD, TNF receptor associated death domain.
current paper indicating that IL-4 dependent rapid in situ prolifer-
ation of local macrophages in Th2-biased inflammation accounts
for extension of tissue alternatively activated macrophages (AAM),
has challenged our prevailing understanding of a predominant
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monocytic contribution to augmented hepatic macrophage pool
and sparked intensive debate (Jenkins et al., 2011; Tacke and
Kurts, 2011). Indeed, under certain circumstances the intrahepatic
macrophage infiltrate might actually be preferentially polarized
towards the M2 phenotype (synonymous for AAM) as it has been
observed in acetaminophen (APAP) treated mice by Holt et al.
(2008). Congruently, these cells elicited a protective role by pro-
moting inflammation resolution and tissue repair. Yet, as far as
other experimental models of ALI are concerned, it is tempt-
ing to speculate that macrophage actions in these conditions
are rather dominated by classically activated M1 macrophages
(CAM) emanating from infiltrating monocytes. This hypothesis
is supported by observations in acute carbon tetrachloride (CCl4)
mediated liver injury in mice. Upon injury, the fraction of Ly6chi
CD11b+ F4/80+ monocytes, representing the peripheral inflam-
matory monocyte subset, is significantly enlarged, whereas Ly6clo
CD11b+ F4/80− or Ly6clo CD11b− F4/80++ cells, corresponding
to either unconventional or resident macrophages, remain stable
(Karlmark et al., 2009). Thus, the major body of evidence indi-
cates that a large proportion of intrahepatic macrophages directly
derives from blood-borne monocytes in conditions of experi-
mental ALI. However, a thorough inspection of the nature of
infiltrating macrophages is warranted, and it is likely that the para-
mount macrophage phenotype strongly depends on the respective
injury model.
Monocyte migration into the liver is facilitated by a profound
secretion of CCL2 (MCP-1) and presumably other chemokines by
parenchymal and non-parenchymal liver cells. Liver macrophages
represent a vigorous source of CCL2 (Karlmark et al., 2008).
CCL2 is secreted and released into the systemic circulation induc-
ing monocyte egress from the bone-marrow. However, available
research activity has failed to elucidate a direct role of CCL2 in the
transendothelial migration of monocyte into the abluminal liver
compartment (Karlmark et al., 2009).
PHYSIOLOGICAL STIMULI TRIGGER IMMUNE MODULATORY
RESPONSES IN KCs
Under homeostatic conditions KC response to stimulation with
physiologically low levels of LPS is considered to restrict inflam-
mation (Knolle and Gerken, 2000). Although KCs also secrete
proinflammatory cytokines like TNF-alpha in the steady state
context, this response may be too faint to elicit overt inflam-
mation and is seemingly blunted by the concomitant release of
anti-inflammatory signals. In fact, TNF-alpha secreted by KC can
even contribute to dampen T-cell response (Knolle and Gerken,
2000). Various mechanisms are believed to render KCs to anti-
inflammatory cells during homeostasis. Strikingly, KC activation
in response to low LPS concentrations has profound impact on
LSEC biology, emphasizing the close reciprocity between these
two cell types. After low concentrated LPS challenge, hepatic
macrophages secrete immunosuppressive IL-10, which acts in an
autocrine manner on KC, but also paracrine on LSEC. IL-10
entails down-regulation of MHC-II and co-stimulatory molecules
such as CD80 and CD86 on LSEC, thereby abrogating CD4+
T-cell activation (Knolle et al., 1998). Similar effects have been
observed for prostanoids [i.e., Prostaglandin 2a (PGE2)] under
non-inflammatory conditions (Knolle et al., 1998). Besides, naïve
KC themselves are poor allostimulatory T-cell activators due to
low expression of MHC-II, B7-1 (CD80), B7-2 (CD86) and CD40,
and limit DC-induced antigen specific T-cell activation. This may
represent another pathway of T-cell tolerance induction by KCs
(You et al., 2008). Moreover, in vitro studies elucidated that IL-10
and prostanoids decrease expression of certain leukocyte adhesion
molecules (ICAM-1, VCAM-1) on LSEC diminishing leukocyte
endothelial transmigration into the liver parenchyma in home-
ostasis (Knolle and Gerken, 2000). Interestingly, KCs are also capa-
ble of disposing activated neutrophils invading the liver, thereby
confining inflammatory processes (Bilzer et al., 2006). Phagocyto-
sis of apoptotic neutrophil remnants by macrophages also attenu-
ates production of proinflammatory cytokines like IL-1β and IL-8
in a TGF-β1, PGE2, and platelet-activating-factor (PAF) depen-
dent fashion (Fadok et al., 1998). Accordingly, in a more recent
publication it was demonstrated that KC priming with apoptotic
splenocytes enhances production of IL-10 and reduces the release
of proinflammatory signals (TNF-α and nitric oxide) through
the Smad3 pathway after endotoxin challenge. Membrane-bound
TGF-beta on apoptotic cells was reported to be the driving force
of this phenomenon (Zhang et al., 2011). This is conclusive evi-
dence that engulfment of apoptotic cell remnants by KCs favors
tolerogenic immune response, as it has been also confirmed for
“steady state” macrophages in general (Lucas et al., 2006; Chung
et al., 2007). Efferocytosis of neutrophils has been demonstrated to
induce IL-10 and TGF-beta production by macrophages and these
cytokines are also closely linked to tissue repair (Ribeiro-Gomes
et al., 2004; Filardy et al., 2010) Mechanisms of immune tolerance
induction by quiescent KCs are illustrated in Figure 1.
KC ACTIVATION AND ITS PROINFLAMMATORY CONSEQUENCES UPON
ACUTE LIVER INSULTS
The response of KC to acute hazardous events contributes to
hepatocyte killing directly and indirectly. Prelude of KC activa-
tion is the release of intracellular constituents from necrotic cells
due to whatever cause (e.g., chemicals, physical, viral, hypoxia).
The liberation of “danger” signals from inflamed, necrotic, or
hypoxic parenchyma cells and the secretion of complement C5a
directly contribute to KC activation. These endogenous damage-
associated-molecular-pattern-molecules (DAMPs) bind to PRRs.
The nuclear transcription factor high mobility group box-1
(HMGB-1) is a ligand of toll-like receptor 4 (TLR4) Its bind-
ing engages several downstream transcriptional factors (nuclear
factor kappa B, NF-κB, AP-1, IRF-3, STAT-1) and kinases, even-
tually cumulating in upregulated synthesis of proinflammatory
mediators with TNF-alpha being the most intensively studied
mediator (Abu-Amara et al., 2010). Congruently, pharmacolog-
ical inhibition of HMGB-1 by the triterpene glycyrrhizin ame-
liorated liver injury after ischemia-reperfusion in rats (Ogiku
et al., 2011). Exogenous DAMPs (i.e., LPS) accumulating in the
anhepatic phase of liver transplantation through translocation of
intestinal microbes have been evidenced to play a role in TLR4
signaling in ALI as well and boost the inflammatory cascade
(Fiorini et al., 2004). It can be concluded, that KCs are more
sensitized to endotoxins in the presence of an additional hepatic
insult, which lowers the threshold to recruit proinflammatory
signals. Although considered a rather protective mechanism in
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homeostasis, engulfment of apoptotic hepatocytes can result in Fas
ligand and TNF-alpha release by KC promoting tissue injury (Can-
bay et al., 2003), yet contradictory results in fulminant hepatitis
exist (Zhang et al., 2011). After TNF-alpha binds to TNF-R1/TNF-
R2 surface receptor on hepatocytes, downstream cascades via
various domains (TRADD, FADD) imply activation of initiator
caspases 8/9 and executioner caspases 3/6/7, which orchestrate cell
death (Tacke et al., 2009). TNF-alpha and Fas (CD95) binding Fas
ligand (FasL) expression are activated in fulminant hepatic failure
by CD8+-cells, NK-cells, and KCs (Miyagawa-Hayashino et al.,
2007; Malhi and Gores, 2008) and share common molecular path-
ways of instigation of apoptosis (Tacke et al., 2009). Furthermore,
TNF-alpha can mediate caspase-independent launch of cellular
death via formation of ROS and prolonged activation of JNK-
pathway leading to extensive necrosis (Malhi and Gores, 2008).
Concomitantly, TNF-alpha elicits protective antiapoptotic actions
via NF-κB activation, resulting in transcription of survival genes
(e.g., Bcl-xl, cFLIP). It is largely unknown which factors disarrange
the balance of TNF-signaling from the predominate “prosurvival”
side to the “proapoptotic” side in ALI (Malhi and Gores, 2008).
Counterbalancing cytokines released by KCs include IL-4, IL-6,
IL-10, and have shown to play a compensatory role in ALI by
abrogating deleterious TNF signals, among others (Abu-Amara
et al., 2010).
Another detrimental aspect of KC activation is secretion of var-
ious CC- and CXC-motif chemokines by activated KCs, which pro-
mote attraction of polymorphonuclear cells (neutrophil granulo-
cytes), CD4+ T-cells, and monocyte-derived macrophages from
the circulation to the hepatic microvasculature (Adams et al.,
2010). When adhered to their target cell, granulocytes release ROS
that trigger hepatocyte death and intensify resulting liver damage.
This emphasizes the conception of heterogeneous cell types acting
synergistically in ALI. CD4+ T-cell and neutrophil extravasation
is facilitated by the induction of sinusoidal ICAM-1 and VCAM-
1, interacting with the integrins CD11b/CD18 and CD29/49,
through the KC-cytokines TNF-alpha and IL-6 (Sakamoto et al.,
2002; Hanschen et al., 2008). Figure 2 summarizes by which
mechanisms hepatic macrophages contribute to ALI.
MONOCYTE SUBPOPULATIONS POSSESS DISTINCT
PHENOTYPES AND FUNCTIONS
MONOCYTES ARE MACROPHAGE/DENDRITIC CELL PROGENITORS AND
IMMUNE EFFECTOR CELLS
Monocytes link the dramatic processes within the systemic and the
hepatic compartment during ALI and failure by dictating systemic
responses to local incidents and by providing hepatic macrophages
that drive tissue injury. As to general features, monocytes are innate
immune cells endowed with a broad panel of chemokine and PRRs
ensuring their role as a potent antimicrobial and migratory leuko-
cyte subset. They are able to identify a broad range of antigens
and stimuli including dead cells, lipids, and bacterial pathogens
(Geissmann et al., 2010). Based on their heterogeneity and versa-
tility, monocytes exert multiple, occasionally opposed functions,
and it is equivocal to which extent distinct monocyte subsets reflect
diverging maturity stages (Gordon and Taylor, 2005; Geissmann
et al., 2010). Lately, comprehensive phenotyping efforts have indi-
cated that probably a continuum of phenotypes exists while the
circumscribed profiles attributed to the defined subtypes merely
constitute extreme polarizations (Wong et al., 2011). The capac-
ity of rapidly releasing abundant amounts of proinflammatory
cytokines (e.g., TNF-alpha, IL-1beta, IL-6, IL-8), reactive oxygen
species, complement factors, and proteolytic enzymes upon vari-
ous stimulatory events may render them as crucial contributors to
the early systemic inflammatory response of acute and devastating
systemic diseases. Opposite to this, the synthesis of immunosup-
pressive mediators (e.g., IL-10), which has been highlighted by
numerous studies, can drive immune paralysis observed in ALI
(Antoniades et al., 2008). Besides secretion of soluble factors, they
augment the local macrophage pools following transendothelial
migration. Moreover, they give rise to certain DCs (e.g., inflamma-
tory TNF-alpha/iNOS-producing TipDCs) during inflammation
(Tacke and Randolph, 2006) and repopulate tissue macrophages
under physiological conditions (Klein et al., 2007).
DEVELOPMENT OF BLOOD MONOCYTES FROM HEMATOPOIETIC
PRECURSOR CELLS
Monocytes circulate in blood vessels, spleen, and bone-marrow
(Geissmann et al., 2010). Their development entails several pre-
cursor cells ranging from a pluripotent hematopoietic stem cell
over a common myeloid (CMP) to a macrophage/DC progenitor
(MDP) along a path of rising lineage restriction and commit-
ment encompassing additional intermediate stages (Robbins and
Swirski, 2010). This process is under control of the growth factors
Csf-1 (alternatively termed M-CSF; Kawasaki et al., 1985) and IL-
34 (Lin et al., 2008) that both bind to Csf-1R (M-CSFR/CD115;
Wei et al., 2010) and synergistically govern monocyte differentia-
tion in a non-redundant manner (Geissmann et al., 2008). CMPs
are referred to as Lin−Sca−IL-7Ra−CD117lowCD34+CD16+ cells
that exhibit CD115 and CX3CR1 on their surface and differentiate
into macrophages, DCs, and monocytes but not into granulocytes
(Akashi et al., 2000; Fogg et al., 2006; Varol et al., 2007). Develop-
ment from MDP into monocytes occurs in the bone-marrow as
the last step of monocyte differentiation before they exit into cir-
culation. This event that is mainly directed by CCR2/CCL2 inter-
actions (especially upon systemic inflammation), but may involve
other homeostatic pathways such as CXCR4/CXCL12 (Serbina and
Pamer, 2006; Geissmann et al., 2008; Figure 3). The prevalent par-
adigm of the bone-marrow as the sole source of monocytes, how-
ever, has been challenged by more recent investigations. According
to these findings, a certain fraction of circulating monocytes delin-
eates from a splenic reservoir in the cords in the subcapsular red
pulp and does not require CCR2 signals to enter systemic circu-
lation (Swirski et al., 2009). In fact, release from the splenic site
relies on factors including angiotensin II (Swirski et al., 2009).
Concordantly, angiotensin-II-lowering agents like angiotensin-
converting-enzyme inhibitors confined the mobilization of splenic
monocytes in a model of myocardial infarction (Leuschner et al.,
2010). CCR2-independent non-medullar monocyte resources
therefore have to be incorporated in further studies dedicated to
intervene at monocyte allocation in pathological settings.
PHENOTYPE AND FUNCTION OF MURINE “CLASSICAL” MONOCYTES
Irrespective of their human or murine origin, peripheral mono-
cytes are defined by expressing the pan-monocytic markers
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FIGURE 3 | Development and features of murine and human monocyte
subsets. Monocyte development from a common myeloid progenitor
(CMP) occurs in the bone-marrow under the control of M-CSF and IL-34 and
increasing lineage commitment. A macrophage dendritic progenitor (MDP)
gives rise to Ly6chi monocytes and probably also to Ly6clo monocytes.
Bone-marrow egress is directed by CCR2, maybe also by other pathways
such as CXCR4/CXCL12 (not depicted). Peripheral Ly6chi can shuttle back to
the bone-marrow and possibly transdifferentiate into Ly6clo monocytes, a
process that might also occur in the periphery (e.g., in the spleen). Murine
monocyte subsets constantly express F4/80 and CD11b. Classical Ly6chi
are characterized by high expression of CCR2 but only moderate levels of
the fractalkine receptor CX3CR1. Furthermore, they express several
scavenger receptors (e.g., CD32), selectin ligand CD62L, and the integrin
VLA-2. Ly6chi monocytes have a proinflammatory profile since they secrete
inflammatory cytokines, migrate into inflamed tissue and give rise to
inflammatory macrophages (sharing qualities with classical M1
macrophages), and DC subsets. Ly6clo are less abundant in the periphery
and express high CX3CR1, CD86, and LFA-1 whereas CCR2 is almost
absent. They patrol blood vessels by crawling across endothelium. During
inflammation they can rapidly or protracted enter tissue and presumably
develop into macrophages with a rather anti-inflammatory phenotype
eliciting wound repair (reminiscent of M2 macrophages). In homeostasis
they are currently designated as precursor cells of local macrophages and
dendritic cells. Importantly, Ly6Chi derived macrophages can very likely also
acquire anti-inflammatory phenotypes in peripheral tissues such as the
liver. Intermediate Ly6cint are not depicted here. FACS dot plot in the right
upper corner illustrates characteristic distribution of human monocyte
subsets. CCR2 high expressing CD14++CD16− monocytes are termed
classical monocytes, representing the vast majority of circulating
monocytes. Despite phenotypic homology to murine inflammatory Ly6chi
monocytes they release immune suppressive IL-10 upon LPS stimulation. In
turn, intermediate and non-classical monocytes that are defined by the
expression of CD16, display moderate to high CX3CR1 and varying density
of CD14 and are far less abundant, but release various inflammatory
cytokines after challenge with TLR4 and TLR7 agonists. These functions
sharply contrast the rather anti-inflammatory phenotype of Ly6clo
monocytes as their putative murine counterparts. Intermediate monocytes
and classical monocytes have a distinct surface protein profile (e.g., CCR5
is almost exclusively expressed on the intermediate subset) though
functional differences are not fully defined. Abbreviations: CMP, common
myeloid progenitor; GMP, granulocyte myeloid progenitor; IFNg, interferon
gamma; LFA-1, lymphocyte function antigen 1; M-CSF, macrophage
colony-stimulating factor; MDP, macrophage dendritic cell progenitor; NO,
nitric oxide; TipDCs, TNF–iNOS-producing dendritic cells; VLA-2, very late
antigen 2.
CD115/CX3CR1 and they lack expression of surface molecules
such as Nkp-46, CD3, CD19, or CD15 that characterize NK-cells,
T-cells, B-cells, and neutrophils, respectively (Auffray et al., 2009).
In mice discrimination of CD11b+F4/80+ monocyte subtypes
relies on the differential expression levels of Ly6C which is rec-
ognized by the antibody RB6-8C5 (Gr1; Geissmann et al., 2003;
Taylor and Gordon, 2003). Owing to a deficit of functional data,
further separation of murine monocyte subsets on the grounds of
variable CD43 expression, as it has been proposed in the current
nomenclature (Ziegler-Heitbrock et al., 2010), will be neglected
here. Ly6chi (Gr1hi) monocytes constitute comparatively big cells
that are distinguished by CCR2hiCX3CR1lo expression and the
presence of VLA-2 and CD62L adhesion molecules (Taylor and
Gordon, 2003; Robbins and Swirski, 2010; Figure 3). Represent-
ing the major subpopulation, they are designated “inflammatory”
or “classical” monocytes due to the extensive capacity of secret-
ing proinflammatory mediators (i.e., TNF-alpha, iNOs, IL-12,
type 1 interferon) and migrating into inflamed tissues, as it has
been demonstrated for inflamed peritoneum, skin, and infarcted
myocardium (Gordon and Taylor, 2005; Tacke and Randolph,
2006; Robbins and Swirski, 2010). If activating inflammatory sig-
nals hold off, egressed Ly6chi monocyte shuttle back to the bone-
marrow and down-regulate CCR2 expression. Upon inflammatory
stimuli including ALI, Ly6chi monocytes massively translocate
from bone marrow into the circulation and decrease again as the
inflammation abates (Karlmark et al., 2009; Robbins and Swirski,
2010). Subsequent to tissue entry, “classical” monocytes give rise
to macrophages and inflammatory DCs including TipDCs after
MyD88-pathway activation and hence endorse microbial killing
(Strauss-Ayali et al., 2007; Serbina et al., 2008). Likewise, accu-
mulation of these cells also occurs in non-infectious inflamma-
tion settings (Nahrendorf et al., 2007; Robays et al., 2007; Tacke
et al., 2007). In the chronically inflamed liver, Ly6chi monocytes
acquire a phenotype reminiscent of CAM thereby perpetuating
the intrahepatic inflammatory milieu that promotes fibrogenesis
(Karlmark et al., 2009; Tacke and Kurts, 2011). The concept of
the progeny of M1 macrophages from Ly6chi monocytes bases
on observations on mucosal TNF-alpha- and iNOs-producing
macrophages in toxoplasma gondii infection (Dunay et al., 2008).
CHARACTERISTICS OF “NON-CLASSICAL” MONOCYTES IN MICE
In contrast to “classical” monocytes, the functional spectrum of
the less frequent murine Ly6clo (Gr1−) “non-classical” or “resi-
dent” monocytes has not been sufficiently clarified. Controversial
reports have hampered the formation of a clear concept for this
cell type. Some experimental evidence indicates that Ly6clo mono-
cytes originate from Ly6chi cells during maturation (Sunderkotter
et al., 2004; Tacke et al., 2006; Varol et al., 2007), some of the
Ly6clo monocytes, however, develop independently in the bone-
marrow (Geissmann et al., 2003; Hanna et al., 2011). It is well
acknowledged, that “non-classical” monocytes have the potential
to home to uninflamed tissue in a G-protein-dependent man-
ner and thus renew local macrophages and DCs, whereas tissue
inflammation does not induce Ly6clo monocyte recruitment in
early phases of inflammation (Geissmann et al., 2003). Further-
more, their human counterpart cells (CD16+ monocytes) were
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capable of reversely transmigrating across unstimulated human
umbilical vein endothelial cells (HUVEC), a process that involved
the adoption of a DC-like profile (Randolph et al., 2002). Consecu-
tive investigations, however, indicated that Ly6clo monocytes con-
stantly crawl in the lumen of the blood vessels across the endothe-
lial cell layer, mediated by the integrin LFA-1 and CX3CL1, and
sense the subjacent space for danger signals (Auffray et al., 2007).
Yet, when manifest inflammatory processes are absent, Ly6clo
monocytes exhibited very low tendency to extravasate. In turn,
during acute Listeria monocytogenes infection patrolling “non-
classical” monocytes rapidly transmigrate toward the local irritant
stimulus and transiently produce inflammatory cytokines (Auffray
et al., 2009). As inflammation evolves, Ly6clo then might differen-
tiate into alternatively activated (M2) macrophages that suppress
inflammation and convey repair, angiogenesis, and wound healing
(Nahrendorf et al., 2007; Auffray et al., 2009). CCR2 expres-
sion of murine Ly6clo is low to absent in agreement with a
rather anti-inflammatory profile. Instead, they express abundant
CX3CR1, which might potentially explain their longer live-span,
and express different adhesion molecules (high LFA-1 expression)
in comparison to the “classical” counterpart (Figure 3).
DIVERGENT PROPERTIES OF HUMANMONOCYTE SUBTYPES
Despite increasing knowledge about phenotypic and genetic con-
gruency between murine and human monocyte subsets (Ingersoll
et al., 2010), there seem to be profound functional disparities
between monocytes in different species. In addition, some dif-
ferences on the phenotype level are present as well that hinder
the experimental analysis of monocytes in acute murine liver
injury. For instance, differential regulation of monocytic HLA-DR
expression in ALI cannot be studied in mice since HLA-DR is not
present on circulating monocytes in that species. By now the dis-
tinction of three different human monocyte subpopulations has
been implemented in the official nomenclature (Ziegler-Heitbrock
et al., 2010; Wong et al., 2011; Zawada et al., 2011). Accounting for
approximately 90% of circulating monocytes, human “classical”
monocytes are CD14++CD16− cells with high levels of CCR2 and
low levels of CX3CR1 thereby closely resembling murine Ly6chi.
They feature relatively high CCR1, CXCR1, CXCR2, CXCR4,
CD32, CD62L and CD64 expression but only low levels HLA-
DR and have significant phagocytic activity (Wong et al., 2011;
Zimmermann et al., 2011). Following endothelial transmigration,
these cells tend to persist in the subendothelial space and develop
into macrophages whereas CD16 positive monocytes are predis-
posed to develop into migratory DCs with T-cell-stimulatory
capacity (Randolph et al., 2002). Monocytes that display CD16
on their surface are now further divided into an “intermedi-
ate” subset (with maintained high expression of CD14, therefore
termed CD14++CD16+) and “non-classical” CD14lo cells with
equal to increased amounts of CD16 (CD14+CD16++; Figure 3).
Some striking discrepancies exist between the latter subsets.“Inter-
mediate” monocytes exhibit highest HLA-DR, mannose receptor
CD206 [a M2 marker (Zimmermann and Adams, unpublished
data)] and CCR5 levels, whereas the fractalkine receptor is most
abundant on the CD14lo subtype (Wong et al., 2011; Zawada et al.,
2011). Selective CD206 expression by CD14++CD16+ cells might
refer to their preferential capacity to give rise to AAM, though
this needs functional confirmation. Both subsets show compara-
ble levels of CD32 and only marginal CCR2 expression (Zawada
et al., 2011). Functional differences between the CD16+ mono-
cytes are still somewhat ill-defined and the majority of available
functional data does not distinguish between the various subtypes.
“Intermediate” monocytes seem to be specifically involved in HIV
infection, possibly because of their CCR5 expression that confers
viral cell-entry in CCR5-tropic-HIV-1-(M)-strains (Jaworowski
et al., 2007). The prominent feature of CD16+ monocytes to
release proinflammatory mediators upon in vitro stimulation with
LPS has been attributed to the CD14hi expression subset (Grage-
Griebenow et al., 2001), whereas, according to another study,
CD14lo monocytes show only weak phagocytic activity and secrete
only low amounts of cytokines and reactive oxygen species after
LPS exposure but synthesize TNF-alpha, IL-1beta as well as CCL3
subsequent to viral and nucleic acid stimuli involving activated
TLR7–TLR8–MyD88–MEK pathway (Cros et al., 2010). Similar to
murine Ly6clo monocytes, these cells patrol in the blood vessels in
an integrin-dependent manner (Cros et al., 2010).
EXPANSION AND FUNCTION OF CD16 EXPRESSING MONOCYTES
DURING HUMAN DISEASES
Regardless of the heterogeneity of CD16+ monocytes, there are a
multitude of pathological conditions leading to an expansion of
the minor CD16+ subset. Increased proportions of CD16+mono-
cytes in “sterile” inflammation have been reported in rheuma-
toid arthritis (Kawanaka et al., 2002; Wijngaarden et al., 2003),
hemodialysis (Nockher and Scherberich, 1998), and atheroscle-
rosis/coronary artery disease (Rothe et al., 1996; Schlitt et al.,
2004), among others, and frequently mirrored disease activity
and severity. Infectious diseases such as HIV (Thieblemont et al.,
1995), erysipelas (Horelt et al., 2002), and bacterial sepsis (Fingerle
et al., 1993) also exhibit a substantial rise in CD16+ monocytes.
Interestingly, peripheral counts of this subset were pronounced in
patients with Gram-negative bacteremia (Herra et al., 1996), which
is highly prevalent in patients with ALF. Resolution of inflam-
mation and successful antimicrobial treatment result in decline
of peripheral monocytes (Horelt et al., 2002). In the context of
liver disease, a shift in distribution of peripheral monocytes and
monocyte-derived hepatic macrophage subsets toward the CD16+
subtype indicates disease progression and is highest in patients
with end-stage Child C cirrhosis (Zimmermann et al., 2010).
Furthermore, under constant flow mimicking sinusoidal shear
stress CD16+ monocytes are more prone to transmigrate across
TNF-alpha/IFN-gamma stimulated hepatic sinusoidal endothe-
lium than their CD16− counterpart (Liaskou et al., unpublished
data). It is obvious to anticipate that CD16+ monocytes also
expand in ALF, yet, investigations in this subject are still pending.
The total number of monocytes harshly decline in acetaminophen-
induced ALF (AALF), but the relative distribution of monocyte
subsets was not addressed in this study (Antoniades et al., 2012).
In sharp contrast to their putative murine counterparts, CD16+
monocytes are tagged “proinflammatory” since in vitro they
are potent producers of proinflammatory mediators such as
TNF-alpha, IL-12, IFN-gamma, CCL3, CCL4, CXCL9, and nitric
oxide after stimulation with either TLR2-/TLR4-agonists, tumors
or even spontaneously. They hence might pivotally contribute to
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systemic enhancement of the proinflammatory environment in
ALF (Belge et al., 2002; Szaflarska et al., 2004; Zimmermann et al.,
2010). Vice versa, human CD16− monocytes secrete immuno-
suppressant IL-10, which is nearly absent on protein as well as
transcriptional level in the CD16+ subset. They thus clearly feature
anti-inflammatory traits (Mizuno et al., 2005; Zimmermann et al.,
2010; Figure 3). Of note, the profound discrepancies between sim-
ilar phenotypic features and functional disparities between murine
and their putative homolog human monocyte subpopulations is
beyond clarification. In addition, the biological relevance of proin-
flammatory qualities attributed to human CD16+ monocytes has
not been completely uncovered but future scientific studies will
certainly help to elucidate open questions in that controversy.
MONOCYTES/MACROPHAGES IN EXPERIMENTAL MODELS
OF ACUTE LIVER INJURY
Given the heterogeneous nature of the various triggers of ALI
as a common sequela, it is a rational approach to use different
experimental models in order to shed light on the pathogenesis
of this disorder. Despite a broad panel of different models of ALI
in rodents and other mammals, there are currently no experi-
mental models that appropriately reproduce all aspects of acute
human liver injury/failure (Newsome et al., 2000). Importantly,
the diagnostic King’s college criteria for ALI and ALF in human
mainly incorporate biochemical and clinical deteriorations that
are scarcely applicable to (small) animals (Tunon et al., 2009).
Despite prevailing limitations, animal models have unraveled rel-
evant aspects of macrophage action in this devastating disease
condition. Selected models will be summarized in this paragraph.
Approaches that aimed at ablating monocyte/macrophage migra-
tion and function by targeting chemokine pathways are discussed
in subsequent sections.
EXPERIMENTAL MODELS OF ALI INVOLVING CHEMICAL SUBSTANCES
Chemical models of ALI comprise substances such as aceta-
minophen (APAP),galactosamine and LPS (GalN–LPS), the plant-
derived lectin Concanavalin A (ConA), double-stranded RNA
(polyI:C), alpha-Galactosylceramide (alpha-GalCer), single endo-
toxins, carbon tetrachloride (CCl4), CpG, DMSO, CD40L, aman-
itin, and thioacetamide, but only very few have been used to
substantially unravel role and mechanisms of macrophage activity
in this disease complex (Wu et al., 2010).
Concanavalin A
Concanavalin A (ConA) is a plant mitogen with carbohydrate-
binding (lectin) properties extracted from Canavalia ensiformis,
which causes a vigorous CD4+ T-cell stimulation resulting in
hepatic TNF-related hepatic necrosis after single administration
(Mizuhara et al., 1994). Initial evidence for a causative role of KCs
in ALI following ConA challenge stems from a study involving
gadolinium-chloride-(GdCl3)-treatment (Okamoto et al., 1998).
GdCl3 reduces KCs and compromises their function, though a
complete depletion is not achieved (Michael et al., 1999). Reduc-
tion/alteration of KCs yielded less damage, though intrahepatic
TNF-alpha expression was not changed (Okamoto et al., 1998).
Based on a similar strategy of KC manipulation, liver injury could
be markedly ameliorated, accompanied by reduced intrahepatic
cytokine levels (including TNF-alpha) and diminished infiltration
of CD4+ T-cells, in another study (Morita et al., 2003). Schu-
mann et al. (2000) could demonstrate that KC elimination by
clodronate-loaded liposomes significantly restricted the spread-
ing of focal confluent necroses. This phenomenon was attributed
to KC-dominant TNF-alpha secretion in that model. However,
systemic levels of TNF-alpha were not affected and injection of
soluble rmuTNF could not abolish the protective effect of KC-
ablation (Schumann et al., 2000). The latter observation suggests
that membrane-bound TNF-alpha is pivotal in driving ConA-
induced liver injury. The authors could also observe a harsh decline
of systemic IL-6 levels, a cytokine which has hepatoprotective qual-
ities and governs liver regeneration (Streetz et al., 2003; Tacke
et al., 2009). This might appear contradictory to the blunted liver
damage observed here, since IL-6-deficient mice were more sus-
ceptible to ConA-mediated fulminant hepatitis than wild-type
animals (Tagawa et al., 2000). Succeeding investigations under-
scored the relevance of KCs for the contribution to a dominant
Th1 immune response in the ConA model (Chen et al., 2011). Of
note, several studies demonstrated that repetitive sublethal ConA
injections induced immunotolerance, which could be attributed to
instigation of IL-10 production by KCs acting synergistically with
regulatory T-cells (Erhardt et al., 2007; Erhardt and Tiegs, 2010).
Mechanistically, inhibition of NF-κB activation in KCs by intra-
portally injected decoy oligonucleotide-loaded gelated particles
during ConA hepatitis but not ischemia/reperfusion related liver
injury led to diminished TNF-alpha production and reduced phos-
phorylation of the proapoptotic jun N-terminal kinase (JNK), that
essentially drives hepatocyte apoptosis (Hoffmann et al., 2009).
D-galactosamine/lipopolysaccharide
The coadministration of d-galactosamine and LPS (GalN/LPS)
is a model of synchronous liver injury and endotoxin-shock and
is governed by monocyte/macrophage-released TNF-alpha that
essentially induces hepatocyte apoptosis (Josephs et al., 2000; Stu-
art et al., 2011). In accordance to the ConA model described
precedingly, selective pharmacological inhibition of the NF-κB
downstream cascade in KCs abrogated TNF-alpha synthesis and
blunted liver damage (Hoffmann et al., 2009). TNF-alpha release
by KCs in this model is negatively modulated by the Ron receptor
tyrosine kinase and Lys-Cre Ron TKft/ft mice with a conditional
myeloid-specific Ron deletion featured exacerbated damage and
increased lethality in response GalN/LPS induced injury (Stu-
art et al., 2011). Ron deficient mice correspondingly had higher
Tnf-alpha gene transcription (Stuart et al., 2011).
Acetaminophen (APAP)
In terms of clinical relevance and dose-dependent toxicity, APAP
meets the criteria for a suitable model of ALF (Newsome et al.,
2000). Following exposure to toxic doses, physiological detoxi-
fying pathways (glucuronidation, sulfation, renal excretion) are
depleted and acetaminophen enters Cytochrom-P450 metabolism,
which in turn yields abundant production of the toxic metabolite
N -acetyl-p-benzoquinoneimine (NAQI; Corcoran et al., 1980).
Centrilobular necrosis and fulminant organ failure emerge when
protective glutathione levels are exhausted (Roberts et al., 1990).
This is significantly accelerated during concomitant exposure to
Frontiers in Physiology | Gastrointestinal Sciences October 2012 | Volume 3 | Article 56 | 8
Zimmermann et al. Monocytes/macrophages in acute liver failure
cytochrom-P450-inducing drugs and alcohol. Covalent binding
and arylation of important cell proteins by NAQI results in loss
of protein function and profoundly impairs organelle and cell
integrity (Cohen and Khairallah, 1997). Hepatic macrophages
contribute to hepatotoxicity via different mechanisms encom-
passing the formation of nitric oxide and superoxide that react
together to produce peroxynitrite, which again exhibits hydroxyl
radical-like activity (Michael et al., 1999). Importantly, KCs release
a multitude of inflammatory cytokines, in particular TNF-alpha,
after toxic APAP exposure (Laskin et al., 1986). In line, earlier
studies reported that GdCl3 treatment prior to APAP challenge in
mice significantly attenuated liver damage and associated mor-
tality (Blazka et al., 1995; Laskin et al., 1995; Michael et al.,
1999). Subsequent series of experiments employing clodronate-
loaded liposomes, a strategy that enables more profound KC
depletion than GdCl3, showed contradictory results. Pretreatment
with clodronate liposomes led to almost complete KC depletion,
decrease of intrahepatic immune modulatory cytokines such as
IL-6, IL-10, or IL-18, and markedly enhanced susceptibility to
acetaminophen (Ju et al., 2002). IL-10 was demonstrated to dimin-
ish APAP-associated hepatic necrosis and lethality (Bourdi et al.,
2002). In support of this work, Holt et al. (2010) found that
KC-dependent maintenance of liver sinusoidal endothelial cell
integrity is another contributory factor to hepatoprotection dur-
ing acetaminophen toxicity. Ambiguously, a protective role of KCs
was not reproducible in a successive study also using clodronate
liposomes (Campion et al., 2008). Conclusively, the precise nature
of the functional dichotomy of hepatic macrophages in APAP
toxicity is yet to be elucidated. A more recent study portended
that opposing roles of hepatic macrophages might be attributable
to cell origin since prolonged infiltration of monocyte-derived
macrophages clearly promoted resistance to APAP damage (Holt
et al., 2008). The concept of sequential immigration of dif-
ferent macrophage subpopulations was also evidenced in acute
thioacetamide-mediated injury (Mori et al., 2009), in which KC-
inactivation alleviates the extent of liver deterioration and accel-
erates liver regeneration (Andres et al., 2003; Bautista et al., 2010).
Of note, beneficial properties of recently infiltrated macrophages
were note reproducible in the carbon tetrachloride (CCl4) model
of acute injury (Karlmark et al., 2009; Mitchell et al., 2009).
Carbon tetrachloride (CCl4)
CCl4 is widely employed in liver research as it reliably induces
an acute toxic liver injury and even liver fibrosis within several
weeks after repetitive injection. Cessation of CCl4 administration
after single and long-term use allows the study of injury regression
(Berres et al., 2010; Karlmark et al., 2010). Acute hepatic toxicity
is a consequence of carbon-tetrachloride-induced formation of
a highly reactive carbon-entered trichloromethyl radical through
cytochrom-P450 isoenzymes that interacts with hepatic proteins
as well as lipids and deteriorates cellular membranes (Luckey and
Petersen, 2001). Rapid centrilobular damage succeeds already after
one injection. CCl4-exposure entails upregulation of Tnf-alpha,
Il-1beta, Il-6, Tgf-beta, and cyclooxygenase-2 mRNA transcripts
and synthesis of reactive oxygen species plus eicosanoids in KCs
(Alric et al., 2000; Luckey and Petersen, 2001). However, mecha-
nistic evidence for a relevant role of KCs in CCl4-mediated liver
injury is scarce. Transient elimination of blood monocytes and
hepatic macrophages cells prior to toxin-injection did not alter
the magnitude of resulting liver damage, suggesting that mono-
cytes/macrophages do not endorse acute liver damage in that
specific model, but rather modify the subsequent inflammatory
response within the injured liver. These findings were corrobo-
rated by data from chemokine-directed targeting of infiltrating
macrophages in the same work (Karlmark et al., 2009). Basi-
cally, the secretory profile of hepatic macrophages might implicate
both harmful and beneficial effects for the hepatic outcome of
CCl4-mediated injury, since it has been shown that disruption of
TNF-alpha-pathways partially restores liver integrity (Morio et al.,
2001), whereas mice lacking the gene for nitric oxidase synthase
(NOS II) or IL-6 are more susceptible to liver damage in that
model (Morio et al., 2001; Bansal et al., 2005). Noteworthy, the
reliability of CCl4 for studying pathogenesis of ALI is hampered
by the considerable inherent variability of this model related to
differences in species, age, and development of the metabolizing
cytochrome-P-450 system (Newsome et al., 2000).
KC IN THE MOLECULAR CASCADE OF ISCHEMIA/REPERFUSION AS A
SURGICAL MODEL OF ALI
Acute liver damage is an important sequel to hepatic
ischemia/reperfusion (I/R) injury as it occurs in the clinical set-
tings of trauma, shock of any cause, transient surgical interruption
of hepatic blood flow and liver transplantation (Howard et al.,
1990). A vast array of I/R animal studies have highlighted the role
of inflammatory cytokines, reactive oxygen species, and seques-
tration/activation of leukocytes in the self-amplified cytotoxic
cascade entailing the demise of liver parenchyma (Zhai et al.,
2011). During I/R injury, KC swelling as a consequence of ion
channel breakdown due to the depletion of adenosine triphos-
phate (ATP) contributes to devastating hepatic microcirculatory
dysfunction. Moreover, complement factors and lymphocyte-
released IFN-gamma are strong activating stimuli for KCs (Wanner
et al., 1996). NADPH oxidase activation in KCs has been shown
to be an integral component in the postischemic injury phase
(Jaeschke, 2003). They secrete critical amounts of TNF-alpha, IL-
1beta, promigratory chemokines, and free radicals. These humoral
factors and reactive species directly promote hepatocyte death,
sinusoidal endothelial damage and favor leukocyte adhesion, and
infiltration, all of which processes propagate I/R injury (Abu-
Amara et al., 2010). Monocyte-derived macrophages enter the liver
in the rather late postischemic phase and sustain the inflamma-
tory milieu responsible for continuous destruction of local tissue
(Zhai et al., 2011). In the scope of ongoing liver inflammation
due to I/R injury, KCs are able to change from a proinflamma-
tory to a more immune modulatory phenotype by releasing IL-10
(Bamboat et al., 2010; Ellett et al., 2010).
In agreement with the well-described inflammatory prop-
erties of hepatic macrophages in that model, many investiga-
tors observed that KC blockade improves ischemic liver injury
(Hardonk et al., 1992; Giakoustidis et al., 2003, 2006; Tomiyama
et al., 2008). Ellett et al. (2010) demonstrated an imbalanced
cytokine milieu in the absence of KC in I/R combined with
bowel congestion, presumably owing to a lack of protective IL-
10. This was associated with largely enhanced liver injury and
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increased mortality. Beneficial effects of hepatic macrophages
during ischemic insults could be attributed to liver resident but
not infiltrating macrophages in a previous paper, that elegantly
delineated the differential contribution of resident and infiltrating
macrophages by using clodronate liposomes in CD11b diphtheria
toxin receptor (DTR) mice. The KC-specific antioxidant heme-
oxygenase was described to be protective in this model (Richards
et al., 2010). Conflicting results regarding KC function in I/R injury
may be explained by substantial methodic differences in KC deple-
tion in the pertinent studies (e.g., GdCl3 vs. clodronate liposomes)
or by the fact that the different observations merely depict one
extreme of the diametrically opposed biphasic functions of hepatic
macrophages in ALI. In conclusion, the net effect of KC activity in
I/R injury remains to be clarified.
MONOCYTE AND MACROPHAGE RELATED CHEMOKINE
PATHWAYS IN ACUTE LIVER INJURY
CLASSIFICATION OF THE CHEMOKINE SYSTEM
Chemokines belong to a family of heparin-binding small promi-
gratory cytokines that orchestrate the trafficking of immune cells,
which is indispensable for immune cell functions in homeostasis
(recirculation of leukocytes to secondary lymphoid tissues) and
inflammation. They have received tremendous attention through-
out the last years in terms of their function in liver inflammation
and resulting fibrosis and many studies have investigated whether
modifications of chemokine pathways could imply therapeutic
benefits (comprehensively reviewed in Zimmermann and Tacke,
2011). Apart from CX3CR1 and CCR2 monocyte differentially
express CCR1, CCR5, CCR8, CXCR1, CXCR2, and CXCR4 that
may all influence their migratory fate to varying degrees (Gordon
and Taylor, 2005; Zawada et al., 2011; Zimmermann and Tacke,
2011).
CCL2 (MONOCYTE-CHEMOATTRACTANT-PROTEIN-1) IN ACUTE LIVER
INJURY
CCL2 (monocyte-chemoattractant-protein-1, MCP-1) is the piv-
otal ligand of CCR2 and has been intensively studied in the context
of liver injury. Many intrahepatic cell subsets release CCL2 upon a
deleterious stimulus encompassing hepatocytes (Dambach et al.,
2002) and non-parenchymal cells such as KCs (Jaeschke and Smith,
1997; Marra et al., 1998; Dambach et al., 2002; Seki et al., 2007),
biliary epithelial cells (Marra et al., 1998; Tsuneyama et al., 2001;
Kruglov et al., 2006; Harada et al., 2011), and quiescent or acti-
vated HSC (Marra et al., 1993, 1995, 1998) supporting the notion
that CCL2-release represents an ubiquitous inflammatory path-
way that is highly conserved in cells from entirely distinct onto-
genic backgrounds. In the context of ALI, CCL2 as well as other
proinflammatory chemokines such as CCL3 (MIP-1alpha), CCL4
(MIP-1beta), CXCL9 (MIG), and CXCL10 (IP-10) are secreted in
response to TNF-alpha, IL-1alpha, IL-1beta, LPS, and reactive oxy-
gen species stimuli originating from damaged hepatocytes, KCs,
intestinal bacteria, and other sources (Czaja et al., 1994; Heymann
et al., 2009). Interestingly, hepatic upregulation of CCL2 marks
a very early event in the course of acute hepatic damage, since
it is detectable in the first 1–4 h after the onset of CCl4-induced
liver injury (Czaja et al., 1994; Marra et al., 1999; Leifeld et al.,
2003; Karlmark et al., 2009). First evidence of the relevance of
CCL2 in ALI delineate from a study involving CCl4- and galac-
tosamine exposed rats, that displayed marked increase of CCL2
(Czaja et al., 1994). Apart from CCl4-mediated ALI, induction of
CCL2 expression has been observed in GalN/LPS (Leifeld et al.,
2003), thioacetamide (Mori et al., 2009), ConA (Ajuebor et al.,
2003; Leifeld et al., 2003), and drug-(APAP)-induced liver toxic-
ity (Dambach et al., 2002). In human ALF increased CCL2 levels
have been detected in various studies (Leifeld et al., 2003; James
et al., 2005; Roth et al., 2009; Antoniades et al., 2012). Of note,
CCL2 serum concentrations in a pediatric study cohort correlated
with clinical disease severity, transaminase levels, and coagulopa-
thy (James et al., 2005) and highest CCL2 levels were associated
with fatal outcome in patients with acetaminophen-induced liver
failure (Antoniades et al., 2012). Functional cues for the impor-
tance of increased intrahepatic chemokines for the hepatopetal
trafficking of human monocytes/macrophages in ALF arise from
one study that used homogenized liver samples from ALF patients
livers containing elevated amounts of CCL2. Therein, a chemotac-
tic stimulus on monocytes could be observed (Leifeld et al., 2003).
Chemotaxis was significantly decreased by simultaneous treat-
ment with CCL2, CCL3, CCL4, and CCL5 neutralizing antibodies.
The latter chemokines were comparably elevated in acute human
liver failure specimen suggesting that they also might contribute to
the monocyte/macrophage attraction in this disease (Leifeld et al.,
2003).
CCR2 IN ACUTE LIVER INJURY
Experimental studies involving rodents with genetic CCR2 defi-
ciency have shed light onto the functional relevance of the
CCR2/CCL2 axis for the influx of monocytes/macrophages in ALI.
In a study performed by our group, wild-type mice exhibited a vig-
orous influx of CD11b+ F4/80+ macrophages detectable 4 h and
peaking at 48 h post-CCl4-administration. Macrophage infiltra-
tion paralleled tissue and hepatic CCL2 upregulation suggesting
that CCL2/CCR2 instructed macrophage-tissue-ingress. This was
corroborated by the mitigation of CD45+ cell and macrophage
accumulation in the liver in Ccr2−/− knockout mice occurring
4 h after toxin-challenge (Karlmark et al., 2009). Since CCL2
mainly controls monocyte bone-marrow egress, levels of circu-
lating monocytes declined as well, yet to a lesser extent. Mitchell
et al. (2009) also detected diminished proportions of CD11b+
F4/80+ macrophages as well as their respective blood precur-
sors but not CD11c+ cells post-CCl4-challenge in Ccr2 deficient
mice at an early time-point. In contrast to the previous work,
hepatic damage was reduced in the latter study, as expressed
by lower aminotransferases. This suggests a detrimental role of
CCR2+ infiltrating macrophages in the setting of acute liver dam-
age. Furthermore, the critical upregulation of the proinflamma-
tory cytokines and chemokines TNF-alpha, IL-1beta, IL-6, CCL2,
CCL3, CXCL9, and CXCL10 was markedly attenuated, which
might provide a possible mechanism for the observed decrease
in liver injury. In addition, this observation implies that invading
macrophages are an important source of inflammatory media-
tors and thereby directly exacerbate tissue harm. Despite this, the
putative disadvantageous effects of CCR2-controled macrophage
influx observed here cannot be readily extrapolated from the
carbon tetrachloride model to other injury settings. Although
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data obtained from various studies involving acetaminophen-
challenged CCR2−/− mice confirmed that genetic disruption of
CCR2 yields less infiltration of macrophages (Dambach et al.,
2002; Holt et al., 2008), CCR2 deletion did not limit hepatic necro-
sis (Dambach et al., 2002) but effectuated increased liver damage
with amplified apoptosis (Hogaboam et al., 2000). Noteworthy,
Dambach et al. (2002) reported augmented serum CCL2 levels
and induction of TNF-alpha in knockout animals in contrast
to the CCl4 model. These findings support the assumption that
immigrating CCR2+ macrophages in APAP-induced ALI convey
their hepatoprotective effect via resolution of inflammation (e.g.,
through induction of neutrophil apoptosis) and direct necrosis
regression due to phagocytosis of cell debris. In line, the induction
of several hallmark genes of a M2 macrophage phenotype (Ym1,
Fizz1, Arg-1) associated with tissue repair and wound healing in
infiltrating macrophages has been reported (Holt et al., 2008).
Concordantly, clearance of necrotic areas in Ccr2−/− animals
was substantially delayed in the reparation phase. The contro-
versy regarding the consequence of disruption of the CCR2/CCL2
axis in acute liver toxicity has been further substantiated by a
study in which CCL2-deficient mice were characterized by delayed
necrosis formation, ameliorated liver enzyme profile, extenuated
elevation of TNF-alpha, lymphotoxin-beta, and reduced oxida-
tive stress after single gastric CCl4 administration (Zamara et al.,
2007). These antithetic results suggest CCR2-independent effects
of CCL2 which have been described in in-vitro-assays before
(Schecter et al., 2004; Kruglov et al., 2006). The proposed protec-
tive role of CCL2 in acute injury settings recapitulates earlier find-
ings indicating that CCL2 neutralization caused enhanced mortal-
ity in a murine model of lethal endotoxemia (Zisman et al., 1997).
A monocyte-independent mechanism of CCL2-related hepato-
protection in acute T-cell mediated hepatitis has been provided
by Ajuebor et al. (2003) demonstrating that CCL2 also directly
hinders IL-4 production by NKT cells.
Importantly, biological effects of CCL2 deficiency in liver injury
may be reverted by the compensatory upregulation of CCL8
(MCP-2) and CCL7 (MCP-3), which also bind to CCR2 and
mediate monocyte recruitment to the liver in L. monocytogenes
infection (Jia et al., 2008). Furthermore, monocyte/macrophage
trafficking to the site of hepatic injury might also occur without
the involvement of chemokines (Shi et al., 2010). Despite these
possible confinements, intriguing data from murine steatohep-
atitis have given proof of the generic feasibility and efficacy of
CCL2 antagonism by small molecules in combating liver diseases
(Baeck et al., 2012), Clinical trials involving CCR2 antagonists
in non-liver disease entities are already at hand. Pharmacological
inhibition of CCL2 by Spiegelmer technology resulted in a pro-
nounced decrease of monocyte infiltration in acute CCl4-induced
toxicity (Baeck et al., 2012). Further insight into the precise mech-
anisms of CCR2/CCL2 in ALI and identification of disease settings
in which modification of this axis might be of avail are required to
benefit from the recent advances in the development of therapeutic
strategies.
CCL25/CCR9 PATHWAY
Apart from the CCR2/CCL2 pathway, other chemokine networks
are likely to promote monocytes/macrophages to enter the acutely
inflamed liver as well. CCR9, a chemokine receptor traditionally
associated with gut-homing properties of CD4+ T-lymphocytes in
response to a CCL25 gradient, has been shown to be expressed on
liver-infiltrating macrophages (Nakamoto et al., 2012). Following
ConA-exposure TNF-alpha expressing CCR9+CD11b+CD11c−
monocytes abundantly accumulated in the liver of wild-type mice
in accordance to increased hepatic ccl25 mRNA expression. In
turn, acute hepatitis was largely prevented in CCR9−/− animals
and severe inflammation could be restored by adoptive transfer
of macrophages from CCR9+/+ mice. Concordantly, antagoniz-
ing CCL25 was able to confine ConA-induced liver damage and
reduced the number of CCR9+ macrophages (Nakamoto et al.,
2012).
CX3CL1 (FRACTALKINE)/CX3CR1 PATHWAY
The CX3CL1 (fractalkine) receptor CX3CR1 is constitutively
expressed on monocytes and represents the predominant
chemokine receptor on the non-classical monocyte subset (Tacke
and Randolph, 2006). It is not only implicated in cell migra-
tion but also controls several pleiotropic effects which are of vital
importance for monocyte biology. In chronic liver injury CX3CL1
hepatic and serum levels are strongly regulated; CX3CR1 elicits
liver protective functions by promoting hepatic macrophage sur-
vival and restricting adoption of a proinflammatory phenotype
(Aoyama et al., 2010; Karlmark et al., 2010). Of note, CX3CR1-
mediated macrophage survival suppresses the monocyte influx
and thus virtually counteracts CCR2/CCL2 transduced promi-
gratory effects in murine experimental injury models (Karlmark
et al., 2010). Besides, CX3CR1 enables human CD16+ mono-
cytes to migrate across inflamed sinusoidal endothelial cell layer
in conjunction with vascular-adhesion-protein-1 (VAP-1; Aspinall
et al., 2010). Data concerning the relevance of CX3CR1/CX3CL1
in ALI is scarce. In situ hybridization of Cx3cl1 and Cx3cr1 revealed
increased expression of both gene transcripts in ALI (Efsen et al.,
2002), although experimental liver damage was not altered in
CX3CR1−/− mice in early phases after CCl4-exposure (Karlmark
et al., 2010). In the later time-course 72–120 h post-injury when
resolution had occurred, intrahepatic CD11b+F4/80+ remained
fairly stable in knockout animals instead of declining as observed
in wild-type controls. In parallel, liver damage was slightly pro-
longed, even though differences were rather humble (Karlmark
et al., 2010). Conclusively, CX3CL1/CX3CR1 interactions might
spur on wound repair, though further investigations are required
to underpin this theory.
IMPLICATIONS OF HUMANMONOCYTE AND MACROPHAGE
ACTIVITY FOR ACUTE LIVER FAILURE
Acute human liver failure is rare clinical syndrome with only
200–500 annual cases in Germany (Canbay et al., 2011). The
resulting paucity of data concerning the role of human mono-
cytes and macrophages in this syndrome significantly hampers
the translation of findings from animal experimental studies into
man. ALF exhibits striking parallels to the systemic inflamma-
tory response syndrome (SIRS) and concomitant compensatory
anti-inflammatory responses (CARS) observed in the evolution to
septic shock, for instance (Antoniades et al., 2008; Possamai et al.,
2010). Multiple organ dysfunction syndrome (MODS) represents
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a frequent common final path of SIRS/CARS and ALF, eventually
leading to death. Therefore, the dysfunction of human mono-
cytes/macrophages in SIRS/CARS may be regarded as a prototype
for the respective processes that govern fatal outcome in ALF. The
concordant acquired disturbances in the innate immune system of
critically ill patients from a liver and a non-liver background have
been extensively presented in a review by Antoniades et al. (2008).
REDUCED MONOCYTIC HLA-DR EXPRESSION AS PROGNOSTIC
MARKER IN ALF
Expression of the MHC-class-II-molecule HLA-DR and ex vivo
cytokine releasing-capacity are the most widely employed tools
to study monocyte activation and function. In seminal work
involving 50 patients with AALF and 20 patients with ALF due
to other causes (NAALF), a dramatic reduced monocytic HLA-
DR expression and declined number of total HLA-DR positive
monocytes as a sign of immune paralysis could be observed in
comparison to patients with stable advance chronic liver disease
or healthy controls. HLA-DR levels were even more decreased
on monocytes isolated from AALF patients who died or were
subjected to liver transplantation in comparison AALF-subjects
with transplant-free survival. The authors consecutively proposed
HLA-DR expression as a marker to predict an unfavorable out-
come in ALF. Simultaneous measurements of proinflammatory
(IL-6, TNF-alpha, IFN-gamma) and anti-inflammatory cytokines
(IL-4, IL-10) revealed highest concentrations in patients with
low HLA-DR expression (Antoniades et al., 2006). The obser-
vation of markedly decreased MHC-class-II-molecule expression
is highly reminiscent of the monocyte phenotype reported in
numerous studies with sepsis and trauma patients and underscores
the vicinity of these clinical conditions (Antoniades et al., 2008).
Indeed, reduction of monocytic HLA-DR expression as marker of
poor prognosis could be recapitulated in patients with acute on
chronic liver injury due to superimposed bleeding and infectious
complications (Wasmuth et al., 2005). In a recent study, Antoni-
ades et al. (2012) detected depletion of circulating monocytes in
AALF patients which was pronounced in individuals who died or
required transplantation.
MONOCYTE-RELEASED TNF-ALPHA AND IL-10
Interestingly, ex vivo analysis showed a reduced capacity of mono-
cytes to secrete TNF-alpha in response to endotoxin stimulation
which was associated with poor outcome (de la Mata et al., 1990;
Wigmore et al., 1998). In conjunction with reduced monocytic
HLA-DR levels this suggests profound monocyte deactivation,
which might contribute to immune paralysis. Immune stunning
in the context of a CARS-like state is a predisposing factor to
bacterial infections frequently aggravating clinical course of ALF
(Antoniades et al., 2008). IL-10 is an inflammation counterbalanc-
ing cytokine that dominates the immune paralysis during CARS.
Unfavorable elevated systemic IL-10 concentrations observed in
ALF might thus be responsible for monocytic dysfunction since
IL-10 dampens TNF-alpha release and reduces HLA-DR expres-
sion in monocytes (Koppelman et al., 1997; Possamai et al., 2010).
Considering the strong capacity of CD16− monocytes to secrete
IL-10, it is conceivable that monocytes are simultaneously a source
of and a target for IL-10. In contrast, CD16+ monocytes likely
release TNF-alpha in conditions of ALF as well, and boost the
SIRS. These oppositional roles, however, have to be scrutinized in
this scenario.
ACTIVITY OF INTRAHEPATIC MACROPHAGES IN HUMAN ALF
There is very sparse data aiming at the hepatic com-
partment in human ALF with respect to macrophages. In
acetaminophen-induced liver failure locally proliferating and
monocyte-derived macrophages accumulate in necrotic areas in
an anti-inflammatory/regenerative niche of high IL-6, IL-10, and
TGF-beta1 concentration (Antoniades et al., 2012). Increased cir-
culating soluble CD163 (a hemoglobin scavenger receptor) levels
in fulminant liver failure have been suggested to mirror intra-
hepatic macrophage activity and were associated with fatality
(Hiraoka et al., 2005; Moller et al., 2007). Immunohistochem-
ical studies of explanted ALF livers revealed marked expansion
of CD68+ macrophages and augmented Fas Ligand expression
by KCs, hinting at the induction of macrophage-mediated hepa-
tocyte apoptosis through Fas–FasL interactions as a pathogenic
pathway in human liver failure (Mita et al., 2005). A Japanese
group proposed massively elevated serum ferritin (>5000 ng/mL)
levels as surrogate marker for excessive macrophage hyperactiv-
ity, comparable to the macrophage activating syndrome (Kotoh
and Takayanagi, 2010). Transarterial injection of 1000 mg methyl-
prednisone via the arteria hepatica propria (a procedure named
TASIT by the authors) at three consecutive days was performed
in 17 patients in a single-center study. In some cases liver biopsies
were obtained prior to and 1 week after the intervention show-
ing a decline of hepatic macrophages post-treatment. In addition,
survival of treated patients exceeded 70%, whereas only 24%
of patients from a conservatively treated control group survived
(Kotoh and Takayanagi, 2010). The authors claim a clinical benefit
of this tool for selected ALI/ALF patients featuring macrophage
hyperactivation as indicated by serum ferritin concentrations.
However, severe limitations in the study design hamper to judge
the true clinical relevance.
CONCLUSION
Acute liver failure is a rare but fatal clinical condition. Despite
its low prevalence it is a significant burden to public health sys-
tems. Some of the hallmark molecular events in ALI have been
unraveled throughout the last decades but a considerable thera-
peutic breakthrough has not been accomplished so far. Indeed,
new medical tools in counterbalancing the devastating inflam-
matory mechanisms in the acutely inflamed liver are required to
prevent liver transplantation and consecutive live-long immuno-
suppressive therapy. Tremendous research efforts have corrobo-
rated the concept that hepatic macrophages are central in the
pathogenesis of acute hepatic injury. Liver resident macrophages
do not only contribute to but frequently initiate the inflamma-
tory cascade after an acute hepatic insult. They are an important
source of the prototypical proinflammatory cytokine TNF-alpha
and other key mediators propagating liver injury. Liver necrosis
as the macroscopic sequel to extensive hepatocyte cell death can
be reverted by depletion of macrophages in many experimen-
tal models. Due to the complexity of the underlying inflam-
matory network, hepatic macrophages do not only compromise
Frontiers in Physiology | Gastrointestinal Sciences October 2012 | Volume 3 | Article 56 | 12
Zimmermann et al. Monocytes/macrophages in acute liver failure
the integrity of liver parenchyma but also integrate sinusoidal
endothelial cells and sessile as well as migrating immune cells into
the detriment cascade. However, as summarized in the present
review, hepatic macrophages are not exclusively deleterious. They
also secrete messengers such as IL-6 or IL-10 that display local
hepatoprotective properties. The ambiguous consequences of KC
activation in the process of liver injury therefore might arise from a
sequential release of pro- and anti-inflammatory cytokines possi-
bly related to a classically or alternatively activated phenotype but
might also be attributable to the origin of hepatic macrophages.
In this light, KC-ablation even impaired liver damage in some sets
of experiments. Furthermore, experimental interventions inhibit-
ing monocyte ingress like disruption of CCR2/CCL2 and other
chemokine pathways have partially deciphered the differential role
of monocyte-derived macrophages in the context of ALI. Newly
recruited macrophages may account for some of the dichoto-
mous functions of hepatic macrophages that have been reported.
Moreover, the nature of the underlying injury seemingly impacts
macrophage function. In conclusion, although the overall contri-
bution of monocytes and hepatic macrophages to acute hepatic
injury may remain elusive, targeting macrophages exhibits a high
potential for improving management of patients with ALF in the
future.
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